In a nutshell This study evaluated the use of high-dose glucocorticoids (GCs) and their impact on the survival outcomes during anti-PD-1 therapy for the treatment of patients with advanced melanoma. The data showed that early high-dose GC use was associated with poorer outcomes after the onset of immune-related side effects. Some background...
Read More
In a nutshell This study compared the effectiveness and safety outcomes of platinum-based chemotherapy and immune checkpoint inhibitors (ICIs) for the treatment of patients with early-stage triple-negative breast cancer (TNBC). The data showed that ICI plus chemotherapy was associated with good outcomes with reduced side effects compared with...
Read More
In a nutshell This study investigated the role of PET/CT scanning in the treatment of patients with recurrent or hard-to-treat B-cell non-Hodgkin’s lymphoma (NHL) after T-cell therapy. This study found that PET/CT scanning helped predict the effectiveness and side effects of treatment for these patients. Some background Chemoimmunotherapy...
Read More
In a nutshell This study looked at the use and response of the Pfizer BioNTech COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma (NHL). It found that patients with NHL undergoing treatment with rituximab (Rituxan)/obinutuzumab (Gazyva) had a poorer immune response to this vaccine, compared to patients without...
Read More
In a nutshell This study evaluated the effectiveness and safety outcomes of talazoparib (Talzenna) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) with mutations in DNA repair genes. The data showed that talazoparib was effective with manageable side effects for these patients. Some background mCRPC is an...
Read More
In a nutshell This study evaluated the effectiveness and safety of triple combination therapy with immune and targeted therapies in patients with stage III-IV melanoma. The data showed that triple combination therapy was associated with increased survival benefits with manageable side effects for these patients. Some background Melanoma is an...
Read More
In a nutshell This study compared acalabrutinib (Calquence) and ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL). The data showed that both drugs had similar effectiveness while acalabrutinib showed fewer cardiovascular side effects compared to ibrutinib. Some background Chronic lymphocytic...
Read More
In a nutshell This study investigated the effectiveness and safety of bevacizumab (Avastin) administered either on the same day or a few days before chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC). The data showed that bevacizumab administered 4 days before chemotherapy significantly improved overall survival with...
Read More
In a nutshell This study reported the effectiveness and safety of longer rituximab (Rituxan) maintenance therapy schedules (more than 2 years) for the treatment of patients with relapsed or refractory (r/r) indolent (painless) non-Hodgkin lymphoma (iNHL). The data showed that maintenance for up to 2 years with rituximab after response to...
Read More
In a nutshell This study evaluated the effectiveness and safety outcomes of ipatasertib (GDC-0068) in combination with abiraterone acetate (Zytiga) plus prednisone (Deltasone) (AAP) for the treatment of patients with previously untreated metastatic castration-resistant prostate cancer (mCRPC). The data showed that ipatasertib plus...
Read More
In a nutshell This study investigated the effectiveness and safety of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor (CAR) T-cell therapy for patients with previously treated relapsed or refractory (r/r) multiple myeloma (MM). The data showed that a single dose of cilta-cel was safe and effective for the treatment of these...
Read More
In a nutshell This study compared the safety and effectiveness between eribulin (Halaven) and non-eribulin-based chemotherapy regimens in patients with advanced breast cancer (BC). The data showed that eribulin significantly improved survival outcomes with manageable side effects in these patients. Some background Advanced BC has spread...
Read More
